Turning Point Therapeutics Leadership

Dr. Jingrong Jean Cui is a renowned oncology drug designer who is the lead inventor of multiple oncology medicines and clinical compounds. Dr. Cui is the Co-Founder, President, and CEO of BlossomHill Therapeutics, Inc., a San Diego based biotech company focusing in addressing urgent unmet medical needs in oncology and autoimmune disorders. Dr. Cui is also the Scientific Founder of Turning Point Therapeutics, Inc. (TP), a San Diego based biotech company focusing on turning point medicines for cancer patients. TP went public on NASDAQ in April 2019 (Ticker: TPTX). Dr. Cui served as TP’s Chief Scientific Officer (October 2013-January 2020) and a member of Board of Directors (October 2013-June 2020). Prior to that, she was Senior Principal Scientist and then Associate Research Fellow at Pfizer (2003-2013). Prior to that, Dr. Cui served as Project Leader and Group Leader at SUGEN, Inc., a Pharmacia Corporation (1999-2003). Dr. Cui has made significant contributions in oncology drug discovery and development. As scientific founder of Turning Point, she focused on solving drug resistance issues in targeted therapies and invented a unique macrocyclic platform to systematically address resistance issues. This novel strategy and approach led to the creation of three clinical compounds: Repotrectinib (TPX-0005), TPX-0022, and TPX-0046 within 6 years since founding the company. Repotrectinib, a ROS1/TRK/ALK inhibitor, is now in Phase 1/2 global clinical trial. TPX-0022, a MET/CSF1R/SRC inhibitor, and TPX-0046, a RET/SRC inhibitor, entered into Phase 1 studies in 2019. At Pfizer, Dr. Cui was the lead inventor of Crizotinib (XALKORI®) and Lorlatinib (LORBRENA®), and worked on several other oncology projects, including SUTENT®. Dr. Cui and her Crizotinib chemistry team at Pfizer were selected for the 38th National Inventor of the Year Award in 2011. She received two Pfizer Worldwide R&D Achievement Awards (2006 and 2012) and Pfizer innovation award in 2011. Dr. Cui was an honoree for the 2013 American Chemical Society’s Heroes of Chemistry Program for the discovery and development of Crizotinib. She was the winner of the inaugural CABS K. Fong Award in Life Sciences in 2013. Dr. Cui received her Ph.D. from The Ohio State University, and her M.S. and B.S. from the University of Science and Technology of China. She obtained her postdoctoral training at Lawrence Berkeley National Laboratory and the University of California Berkeley.

Mohammad Hirmand, M.D., serves as executive vice president and chief medical officer (CMO) of Turning Point Therapeutics, responsible for clinical development, clinical operations and regulatory affairs. Dr. Hirmand has more than 20 years of biotechnology clinical development experience, most recently as CMO of Peloton Therapeutics, which was acquired by Merck in July 2019.

Prior to joining Peloton in 2017, Dr. Hirmand served as CMO of Medivation through its acquisition by Pfizer. He played a vital role in advancing XTANDI® (enzalutamide) through clinical trials that led to its approval by the U.S. Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer. His responsibilities also included the in-licensing and global clinical development of the poly ADP ribose polymerase (PARP) inhibitor, talazoparib. Before his 10-year tenure at Medivation, he held clinical development roles of increasing responsibility at Nuvelo, Inc. (now ARCA Biopharma), SuperGen, Inc. (now Astex Pharmaceuticals, Inc.), Tularik, Inc. (now part of Amgen), and Theravance Biopharma, Inc.

Andrew Partridge is an Exec VP/Chief Commercial Officer at CENTREXION THERAPEUTICS CORP and Exec VP/Chief Commercial Officer at TURNING POINT THERAPEUTICS, INC.. He has experience at Merck & Co., Inc.; Roche holding; and Amgen Inc. and has worked as COO/CCO at CENTREXION THERAPEUTICS CORP and Sr VP/Head:North America Commercial at VERTEX PHARMACEUTICALS INC / MA. Andrew studied at Birmingham City University.

Paolo Tombesi serves as executive vice president and chief financial officer. Mr. Tombesi has more than 30 years of global financial and accounting experience within biotech and pharmaceutical companies. Prior to joining Turning Point Therapeutics, Mr. Tombesi was the chief financial officer of Epizyme, Inc., where he supported the commercial launch of Tazverik (tazemetostat) for the treatment of relapsed or refractory follicular lymphoma, and was responsible for capital funding, treasury, tax and accounting. Prior to Epizyme, he was CFO for Insmed, Inc., where he led financial operations and preparation for the commercial launch of Arikayce (amikacin liposome inhalation suspension). From 2006 to 2014, he served in roles of increasing responsibility for Novartis, including chief financial and administrative officer of Novartis Pharmaceuticals Corporation; managing director and CFO of Novartis Japan; and CFO of the European Oncology division. Earlier in his career, he served in financial roles for Bristol Myers Squibb in the U.S. and Europe, and Unilever and Johnson & Johnson in Italy.

Dr. Jingrong Jean Cui is a renowned oncology drug designer who is the lead inventor of multiple oncology medicines and clinical compounds. Dr. Cui is the Co-Founder, President, and CEO of BlossomHill Therapeutics, Inc., a San Diego based biotech company focusing in addressing urgent unmet medical needs in oncology and autoimmune disorders. Dr. Cui is also the Scientific Founder of Turning Point Therapeutics, Inc. (TP), a San Diego based biotech company focusing on turning point medicines for cancer patients. TP went public on NASDAQ in April 2019 (Ticker: TPTX). Dr. Cui served as TP’s Chief Scientific Officer (October 2013-January 2020) and a member of Board of Directors (October 2013-June 2020). Prior to that, she was Senior Principal Scientist and then Associate Research Fellow at Pfizer (2003-2013). Prior to that, Dr. Cui served as Project Leader and Group Leader at SUGEN, Inc., a Pharmacia Corporation (1999-2003). Dr. Cui has made significant contributions in oncology drug discovery and development. As scientific founder of Turning Point, she focused on solving drug resistance issues in targeted therapies and invented a unique macrocyclic platform to systematically address resistance issues. This novel strategy and approach led to the creation of three clinical compounds: Repotrectinib (TPX-0005), TPX-0022, and TPX-0046 within 6 years since founding the company. Repotrectinib, a ROS1/TRK/ALK inhibitor, is now in Phase 1/2 global clinical trial. TPX-0022, a MET/CSF1R/SRC inhibitor, and TPX-0046, a RET/SRC inhibitor, entered into Phase 1 studies in 2019. At Pfizer, Dr. Cui was the lead inventor of Crizotinib (XALKORI®) and Lorlatinib (LORBRENA®), and worked on several other oncology projects, including SUTENT®. Dr. Cui and her Crizotinib chemistry team at Pfizer were selected for the 38th National Inventor of the Year Award in 2011. She received two Pfizer Worldwide R&D Achievement Awards (2006 and 2012) and Pfizer innovation award in 2011. Dr. Cui was an honoree for the 2013 American Chemical Society’s Heroes of Chemistry Program for the discovery and development of Crizotinib. She was the winner of the inaugural CABS K. Fong Award in Life Sciences in 2013. Dr. Cui received her Ph.D. from The Ohio State University, and her M.S. and B.S. from the University of Science and Technology of China. She obtained her postdoctoral training at Lawrence Berkeley National Laboratory and the University of California Berkeley.

Dr. Jingrong Jean Cui is a renowned oncology drug designer who is the lead inventor of multiple oncology medicines and clinical compounds. Dr. Cui is the Co-Founder, President, and CEO of BlossomHill Therapeutics, Inc., a San Diego based biotech company focusing in addressing urgent unmet medical needs in oncology and autoimmune disorders. Dr. Cui is also the Scientific Founder of Turning Point Therapeutics, Inc. (TP), a San Diego based biotech company focusing on turning point medicines for cancer patients. TP went public on NASDAQ in April 2019 (Ticker: TPTX). Dr. Cui served as TP’s Chief Scientific Officer (October 2013-January 2020) and a member of Board of Directors (October 2013-June 2020). Prior to that, she was Senior Principal Scientist and then Associate Research Fellow at Pfizer (2003-2013). Prior to that, Dr. Cui served as Project Leader and Group Leader at SUGEN, Inc., a Pharmacia Corporation (1999-2003). Dr. Cui has made significant contributions in oncology drug discovery and development. As scientific founder of Turning Point, she focused on solving drug resistance issues in targeted therapies and invented a unique macrocyclic platform to systematically address resistance issues. This novel strategy and approach led to the creation of three clinical compounds: Repotrectinib (TPX-0005), TPX-0022, and TPX-0046 within 6 years since founding the company. Repotrectinib, a ROS1/TRK/ALK inhibitor, is now in Phase 1/2 global clinical trial. TPX-0022, a MET/CSF1R/SRC inhibitor, and TPX-0046, a RET/SRC inhibitor, entered into Phase 1 studies in 2019. At Pfizer, Dr. Cui was the lead inventor of Crizotinib (XALKORI®) and Lorlatinib (LORBRENA®), and worked on several other oncology projects, including SUTENT®. Dr. Cui and her Crizotinib chemistry team at Pfizer were selected for the 38th National Inventor of the Year Award in 2011. She received two Pfizer Worldwide R&D Achievement Awards (2006 and 2012) and Pfizer innovation award in 2011. Dr. Cui was an honoree for the 2013 American Chemical Society’s Heroes of Chemistry Program for the discovery and development of Crizotinib. She was the winner of the inaugural CABS K. Fong Award in Life Sciences in 2013. Dr. Cui received her Ph.D. from The Ohio State University, and her M.S. and B.S. from the University of Science and Technology of China. She obtained her postdoctoral training at Lawrence Berkeley National Laboratory and the University of California Berkeley.